We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Exc | LSE:EXC | London | Ordinary Share | GB00B01JC987 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.04 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.04 | GBX |
Exc (EXC) Share Charts1 Year Exc Chart |
|
1 Month Exc Chart |
Intraday Exc Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/3/2014 | 12:50 | EXC Plc | 530 |
| 27/8/2009 | 17:41 | EXC - The Lazarus Share ? | 15 |
| 30/6/2009 | 08:06 | *** EXC Plc *** | 51 |
| 26/10/2004 | 09:26 | Liquidate Now | 4 |
| 05/4/2000 | 09:22 | eXchange Ј30m German buy | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 11/11/2009 23:40 by knowing For some time there has been very little liquidity in our shares and, as a result, when even very small numbers of shares have been sold, the Company's share price has declined significantly. As a result, it is difficult for shareholders to sell shares at a reasonable price and in reasonable size. |
Posted at 04/11/2009 14:20 by knowing Come on EXC |
Posted at 01/10/2009 15:06 by topinfo PYC next EXCJust out Physiomics Trading Statement TIDMPYC RNS Number : 0816A Physiomics PLC 01 October 2009 ? Trading Update Physiomics plc ("Physiomics" or "the Company") Highlights: * Revenue for year ended 30 June 2009 is expected to exceed the forecast of GBP440k made in July 2008 * Good progress on Lilly collaboration, with license agreement signed in April 2009 * Achievement of second year milestone on Tempo project * Looking to leverage Physiomics' technology for non-pharmaceutical application Trading Update Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to update the market on its trading performance for the financial year ended 30 June 2009. Revenues for the year were stronger than anticipated in a previous trading statement issued on 28 July 2008 and we were able to build on the improvement set out in the Interim statement issued in February 2009. Conversion of debt into equity announced in August 2009 totalling GBP24k has also helped to reduce the deficit in equity shareholders' funds which stood at GBP102k at 31 December 2008. Since the publication of its interim results for the period ended 31 December 2008, Physiomics has made good progress with its collaboration with Eli Lilly and Company ("Lilly"), and in particular has announced on 2 April 2009 a license agreement with Lilly for a customised version of its "ModelPlayer(TM)" for in silico simulations of unspecified anticancer drugs. These are project specific licences. The Company is in discussion with a number of major players in the oncology sector and expects to be able to say more in the near future. Furthermore, Physiomics has announced on 23 June 2009 a successful evaluation, by the European Commission, of the results from the second year of the research program "TEMPO". This is the most important phase of the project and Physiomics' partners will start imminently to verify in an in vivo pre-clinical model the optimal chronotherapeutic schedules produced by Physiomics. When validated, this will served as a base for a further grant application, with the aim to test these chronotherapeutic schedules in a clinic setting. If the TEMPO approach is validated then it has both the potential to evaluate existing oncology compounds to see whether a more efficient dosing regimen is possible as well as helping formulate optimal study protocols for drugs used in combination therapy. This would provide data on the ideal dosing sequence, time interval between doses and amounts to be dosed. The biological models are supported by sophisticated simulation software environments developed by the team these include the Model Player(TM) and a version of the proprietary SystemCell technology running on the IBM "Blue C" super computer at the Institute of Life Sciences at Swansea University. We intend to leverage this technology platform for non-pharmaceutical application and we are looking at diversification in other areas and in particular Synthetic Biology. Commenting on the trading update, Physiomics' Chief Operating Officer, Dr Christophe Chassagnole, said: "We are really pleased to have exceeded our revenue forecast for the last year thanks to the good progress in our collaborations. Based on these achievements plus the recent technical development in the area of combination and scheduling and the potential to branch out into wholly new applications, we are confident that we can stimulate even greater interest in our technology." For further information: Physiomics plc Dr Christophe Chassagnole, COO +44 (0)1865 784980 WH Ireland Limited Katy Mitchell +44 (0) 161 832 2174 |
Posted at 01/10/2009 13:54 by knowing Thing is with EXC that the market has always kept a flat book on the stock. |
Posted at 01/10/2009 11:31 by 0verzeal Can EXC continue and be traded on Plus ?Thanks in anticipation. |
Posted at 01/9/2009 01:11 by tibrahim Guessing it's linked to the increase in oil price, or a contract win for oil equipment or just plain old renewed interest. |
Posted at 28/8/2009 00:13 by knowing Thanks Tib. If they delist from AIM and move to PLUS then this will double or treble from here I am sure. Nobody knows what is happening but the share price action is very interesting. |
Posted at 27/8/2009 11:45 by wenlynn Stockport-based procurement services and equipment rental company EXC Plc (AIM: EXC) is giving "serious consideration" to delisting from the Alternative Investment Market, it said today (July 2009).EXC posted a loss of £1,097,000 (2007: £491,000 loss)for the year to December 2008, mostly due to the £518,000 cost of closing down Manchester-based leather jacket importer David Conrad (International) Ltd. Revenues from continuing operations were £1,468,000, generating a loss of £579,000. Chairman Michael Edelson said the company's sole trading business, Excalibur Ventures Ltd, generated lower levels of revenue than in prior years because customers were spending less due to the global economic slowdown. Excalibur's rental division, which hires out 28 pieces of heavy equipment to construction companies in the Middle East, managed to expand into a full scale operation during the year. It is less optimistic about its new specialised oil procurement services division, which has received no new orders. Losses are expected in the first half of 2009. Edelson said the board was looking at ways to cut group costs and was reviewing its listing in line with "many other AIM quoted companies". EXC Plc was incorporated in 2004 and listed on the AIM of the London Stock Exchange in July of the same year. Shares In Issue 353 Million John Michael Edelson - Chairman Simon Philip Larah - Chief Executive Elliot Richard Fidler - Finance Director Anthony Jack Leon - Non-Executive Director |
Posted at 01/7/2009 21:27 by topvest No, tried to bail out today, but couldn't get rid of 670k shares...surprise suprise. I think it will go private or go on to PLUS. Not worth selling at the price it now is. Still a possibility something will turn up. The directors need to take a pay cut and Excalibur needs to start delivering. Not a total basket case, but fairly close. |
Posted at 22/6/2008 22:53 by tornadodown Excalibur assists its customers in all stages of their procurement needs, from establishing the technical requirements and specifications necessary to assist in the customers budgetary planning, the tendering process and all the way through to successful delivery of equipment in a timely and efficient manner. Excalibur learns quickly the needs of its individual customers in order for it to offer a tailor made service to meet their specific needs and requirements. This can encompass both quick reaction / lead time procurement for urgent needs through to long term design and planning associated with large scale construction, infrastructure or maintenance projects. Excalibur has the capability to either supplement the customers' existing purchasing operations or, alternatively, it can handle them on their behalf. The equipment we offer is of the highest international standards in quality and performance to meet our customers' needs. Excalibur also offers the flexibility of renting or leasing equipment as an alternative to procurement. Excalibur's operations and customers span many time zones and geographical areas enabling us to offer our clients a 7 day a week, 24 hours a day, 365 day a year service. Excalibur prides itself with the provision of a consistently high standard in its operations, which have received ISO 2001 certification. Excalibur maintains these by forming a long term relationship with our customers and providing: efficient supply and information; responsiveness; accountability; commerciality; pro-activity; and predictability. We keep in constant contact with our customers in order to ensure a constant open line of communication. Through our dedicated teams of professional purchasers in Europe, the Middle East and the U.S.A., we can supply items and equipment on demand. Excalibur also meets the logistical needs of our customers utilising international freight forwarders to enable a global reach in sourcing and delivery to all parts of the world. This service enables us to offer the maximum value to our customers by: helping our customers purchase the exact equipment required; ensuring that the equipment is procured at the lowest price possible whilst maintaining the highest quality; and delivering the equipment safely and on time to the exact location specified by our customers. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
